Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03989206
Recruitment Status : Recruiting
First Posted : June 18, 2019
Last Update Posted : December 13, 2021
Sponsor:
Information provided by (Responsible Party):
Galderma R&D

Brief Summary:
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Condition or disease Intervention/treatment Phase
Moderate-to-Severe Atopic Dermatitis Drug: Nemolizumab Phase 3

Detailed Description:
Long-term study to assess the safety and efficacy of nemolizumab in subjects with moderate-to-severe AD

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1700 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis
Actual Study Start Date : December 30, 2019
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : September 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Nemolizumab
Nemolizumab administered via subcutaneous injection
Drug: Nemolizumab
Nemolizumab
Other Name: CD14152




Primary Outcome Measures :
  1. Incidence and Severity of TEAEs [ Time Frame: Baseline to Week 200 ]
  2. Incidence of Serious TEAEs [ Time Frame: Baseline to Week 200 ]
  3. Incidence and Severity of Adverse Events of Special Interest (AESIs) Throughout the Study [ Time Frame: Baseline to Week 200 ]

Secondary Outcome Measures :
  1. Proportion of Participants with IGA score = 0-1 at Each Visit [ Time Frame: Baseline to Week 200 ]
  2. Proportion of Participants with EASI-75 at Each Visit [ Time Frame: Baseline to Week 200 ]
  3. Change and Percent Change From Baseline in Overall Eczema Area and Severity Index (EASI) Score at Each Visit [ Time Frame: Baseline to Week 200 ]
    EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity will be assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score can range from 0 to 72 with higher scores representing greater severity of atopic dermatitis.

  4. Proportion of Participants with IGA ≤ 2 at Each Visit [ Time Frame: Baseline to Week 200 ]
  5. Change and Percent Change From Baseline in SCORAD Score at Each Visit [ Time Frame: Baseline to Week 200 ]
  6. Change and Percent Change From Baseline in Participant-Reported Pruritus Using 10-cm VAS (SCORAD Sub-Component) [ Time Frame: Baseline to Week 200 ]
  7. Change and Percent Change From Baseline in Participant-Reported Sleep Loss Using 10-cm VAS (SCORAD Sub-Component) [ Time Frame: Baseline to Week 200 ]
  8. Proportion of Participants Reporting Low Disease Activity State Based on PGAD at Each Visit [ Time Frame: Baseline to Week 200 ]
  9. Proportion of Participants Satisfied with Study Treatment Based on PGAT at each visit [ Time Frame: Baseline to Week 200 ]
  10. Change from Baseline in Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline to Week 200 ]
  11. Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Total Score at Each Visit Through Week 200 [ Time Frame: Baseline to Week 200 ]
  12. Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Each Visit Through Week 200 [ Time Frame: Baseline to Week 200 ]
  13. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) for Each Subscale at Each Visit Through Week 200 [ Time Frame: Baseline to Week 200 ]
  14. Change From Baseline in Work Productivity and Activity Impairment: Atopic Dermatitis (WPAI:AD) for Each Subscale at Each Visit Through Week 200 [ Time Frame: Baseline to Week 200 ]
  15. Change From Baseline in EuroQoL 5-Dimension (EQ-5D) at Each Visit Through Week 200 [ Time Frame: Baseline to Week 200 ]
  16. Proportion of Participants Receiving Any Rescue Therapy by Rescue Treatment Type at Any Visit During the Treatment Period [ Time Frame: Baseline to Week 200 ]
  17. Time to First Relapse [ Time Frame: Baseline to Week 200 ]
  18. Duration of Remission [ Time Frame: Baseline to Week 200 ]
  19. Time to Permanent Study Drug Discontinuation [ Time Frame: Baseline to Week 200 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Subjects who may benefit from study participation in the opinion of the investigator and had participated in a prior nemolizumab study for AD
  2. Female subjects of childbearing potential (ie, fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an effective and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.

Key Exclusion Criteria:

  1. Subjects who, during their participation in a prior nemolizumab study, experienced an AE which in the opinion of the investigator could indicate that continued treatment with nemolizumab may present an unreasonable risk for the subject.
  2. Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.
  3. Body weight < 30 kg
  4. Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit. Subjects may be rescreened once the infection has resolved. Resolution of COVID-19 infection can be confirmed by recovery assessment methods.
  5. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody)
  6. Any clinically significant issue, based investigator judgement

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03989206


Contacts
Layout table for location contacts
Contact: Galderma Research & Development 817-961-5000 clinical.studies@galderma.com
Contact: Research & Development 817-961-5000 clinical.studies@galderma.com

Locations
Show Show 351 study locations
Sponsors and Collaborators
Galderma R&D
Layout table for additonal information
Responsible Party: Galderma R&D
ClinicalTrials.gov Identifier: NCT03989206    
Other Study ID Numbers: RD.06.SPR.118163
First Posted: June 18, 2019    Key Record Dates
Last Update Posted: December 13, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases